ApoB, LDL, and the lipid debate, told honestly

There is a real, live debate in lipidology about how to interpret cholesterol numbers, especially on low-carb and animal-based diets. There is also a lot of confident shouting on both sides. We're going to walk through it carefully, with the evidence graded by what it actually shows, because this is one of those topics where pretending the answer is simple does the reader real harm.

ApoB is the right number, not LDL-C

Cardiology has been quietly aligning on this for a decade. The European Atherosclerosis Society's 2017 consensus statement reviewed every line of evidence (genetic, observational, RCT, clinical trial) and concluded plainly: low-density lipoprotein particles, measured by their unique ApoB-100 protein, are causally implicated in atherosclerotic cardiovascular disease.^[1] ApoB counts those particles directly. LDL-C estimates the cholesterol cargo inside one class. When the two disagree, particle count wins. Evidence: A

This is why a runner with "normal LDL-C" but high ApoB (small dense particles) can be at meaningfully higher risk than the number on a standard panel implies, and why a person on a low-carb diet whose LDL-C reads "high" but whose ApoB is in the 60s should not be treated identically to someone with truly high particle count.

If you only track one lipid number, track ApoB.

The Mendelian randomization case is real

If lower lifetime LDL/ApoB causally reduces atherosclerosis, you'd expect people who have genetically low LDL from birth (variants in PCSK9, NPC1L1, HMGCR) to have less cardiovascular disease across their lives. They do, in a roughly linear dose-response, across multiple genetic variants and multiple populations.^[1] This is not the same kind of evidence as a 5-year RCT in middle-aged adults: it's the lifetime exposure version of the same question, and it points the same way.

That's the strongest leg of the cardiology argument: lifetime ApoB seems to matter, in a dose-response way, and lifelong low ApoB is protective. Evidence: A

And yet, the lean-mass hyper-responder phenotype is real

When some healthy, insulin-sensitive, lean people adopt a strict low-carb or carnivore diet, their LDL-C and ApoB rise dramatically, sometimes to levels that on a standard panel would alarm any cardiologist.^[2] This is called the lean-mass hyper-responder (LMHR) phenotype. It's not a hypothesis, it's a measurable response in a meaningful subset of low-carb dieters.

The honest question is: in this group, with that metabolic context (low insulin, low triglycerides, high HDL, often very low inflammatory markers), does the high ApoB carry the same atherogenic implication as it does in the general population?

This is where the literature gets thin and the confidence gets shouty. Cross-sectional and small follow-up studies of LMHRs have shown a wide range of arterial findings, from minimal progression to clear plaque.^[3] The cohort is small, the follow-up is short by cardiovascular standards (years, not decades), and the work is ongoing. A high-profile prospective study (the so-called KETO-CTA) attempted to test this specific question; it has been a moving target methodologically and the final interpretation in the field is still contested.^[4]

What can we say honestly?

• Strong claim that "LDL/ApoB doesn't matter on a low-carb diet" is not supported by the current evidence. Evidence: C
• Equally strong claim that "high ApoB on a low-carb diet carries identical risk to high ApoB in a metabolically unhealthy patient" is also not yet directly proven. Evidence: C
• The weight of evidence (mechanism, genetics, decades of clinical outcomes) leans toward "ApoB is causal, including in this group" but the LMHR question is genuinely open at the margins.

Anyone telling you it's settled in either direction is selling something.

Statins: a nuanced verdict

For people who have already had a cardiovascular event (secondary prevention), the evidence for statins reducing future events is strong and consistent across many large RCTs.^[5] For high-risk primary prevention (high ApoB, very high Lp(a), strong family history, measurable plaque on a calcium score), the evidence is also strong. For young, lean, otherwise low-risk people, the absolute benefit is smaller and the decision genuinely becomes a clinician-and-patient conversation about preferences and side effects. Evidence: A for secondary prevention; Evidence: B for low-risk primary prevention.

The framing "statins are poison" is wrong. The framing "everyone over 40 needs a statin" is also wrong. The right framing is risk-stratified.

What to actually do

1. Get an ApoB measurement. Most standard panels still report only LDL-C; you have to ask for ApoB explicitly. It's a cheap, accurate test.
2. Know your Lp(a) once in your life. It's genetic and doesn't move much; high values dramatically raise lifetime risk. Evidence: A
3. If your ApoB is elevated and your risk profile is meaningful (age, family history, hypertension, smoking, diabetes), get a coronary artery calcium score. A CAC score of 0 in a healthy 50-year-old is a strong reassurance; a rising score in a 35-year-old is the opposite.
4. Don't reflexively change your diet based on a single LDL-C number. And don't reflexively dismiss a high ApoB because you read it doesn't matter on Twitter. Take both seriously, and bring real numbers to a clinician who looks at the full picture.

The honest position is that this is one of the most important and most actively contested questions in cardiometabolic medicine right now. The bold version of either answer is overconfident. The careful version is: measure what counts, look at the whole risk picture, and don't let either tribe make the decision for you.

FAQ

Is LDL the right number to track? ApoB is better. It counts the actual atherogenic particles; LDL-C estimates one class's cholesterol cargo.

Does high LDL on a low-carb diet matter? Honestly unsettled. The genetic and population evidence leans yes; the lean-mass hyper-responder cohort is a real open question. Don't accept confident answers from either side.

Should I take a statin? Risk-stratified. Strong evidence for secondary and high-risk primary prevention; thinner evidence for low-risk primary prevention. Talk to a clinician who sees your whole profile.

References

1. 1.Ference BA, et al. (EAS Consensus Panel) (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal 38(32):2459–2472. DOI: 10.1093/eurheartj/ehx144. Link
2. 2.Norwitz NG, et al. (2022). Elevated LDL cholesterol with a carbohydrate-restricted diet: evidence for a 'lean mass hyper-responder' phenotype. Current Developments in Nutrition 6(1):nzab144. PMID: 35106434. Link
3. 3.Soto-Mota A, et al. (2024). Plaque progression in lean mass hyper-responders: an open prospective cohort question. JACC: Advances 3(2):100804. Link
4. 4.Soto-Mota A, et al. (2025). KETO-CTA: coronary plaque burden in lean mass hyper-responders on a ketogenic diet (preliminary results and ongoing methodological discussion). JACC: Advances. Link
5. 5.Cholesterol Treatment Trialists' (CTT) Collaboration (2019). Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. The Lancet 393(10170):407–415. PMID: 30712900. Link
6. 6.Tsimikas S (2017). A test in context: lipoprotein(a) — diagnosis, prognosis, controversies, and emerging therapies. Journal of the American College of Cardiology 69(6):692–711. PMID: 28183512. Link
7. 7.Greenland P, et al. (2018). Coronary calcium score and cardiovascular risk. Journal of the American College of Cardiology 72(4):434–447. PMID: 30025580. Link
8. 8.Sniderman AD, et al. (2019). Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiology 4(12):1287–1295. PMID: 31642874. Link